In a report released today, Les Sulewski from Truist Financial maintained a Hold rating on Bausch Health Companies (BHC – Research Report). The company’s shares closed yesterday at $6.54.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Sulewski is a 3-star analyst with an average return of 8.2% and a 34.92% success rate. Sulewski covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, ANI Pharmaceuticals, and biote.
Bausch Health Companies has an analyst consensus of Hold, with a price target consensus of $8.33, representing a 27.37% upside. In a report released yesterday, Jefferies also downgraded the stock to a Hold with a $8.00 price target.
BHC market cap is currently $2.41B and has a P/E ratio of -13.48.
Read More on BHC:
- Bausch Health downgraded to Hold from Buy at Jefferies
- Bausch Health downgraded at Jefferies with B+L deal catalyst removed
- Bausch Health call volume above normal and directionally bullish
- Bausch Health Retains Bausch + Lomb, Explores New Financial Strategies
- Bausch Health board determines not to move forward with Bausch + Lomb sale